Infantile Neutropenia Clinical Trials

Find Infantile Neutropenia Clinical Trials Near You

Swiss 2024 Fever Monitoring Study: An Double-blinded, Randomized Controlled Multiple Crossover Superiority Trial on Continuous Fever Monitoring in Paediatric Patients With Cancer at Risk for Fever in Neutropenia

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

In children and adolescents undergoing chemotherapy for cancer, fever in neutropenia (FN) is the most frequent potentially lethal complication of chemotherapy for cancer. Emergency hospitalization and empirical treatment with i.v. broad-spectrum antibiotics have reduced lethality from \>50% in certain high risk situations to \<1%. Fever without neutropenia is a further complication requiring emergency evaluation and often emergency treatment. Continuous monitoring of fever leads to earlier fever detection compared to the usual discrete fever measurements performed only for clinical reasons. Earlier detection of fever leads to earlier assessment and treatment and thus can reduce the risk of complications. This study primarily aims to assess, in pediatric patients undergoing chemotherapy for cancer, the efficacy of automated fever alerts resulting from continuous fever monitoring (CFM) using a wearable device (WD), measured by the duration of intravenous antibiotics (i.v. AB) given for any cause.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 month
Maximum Age: 17
Healthy Volunteers: f
View:

• Chemotherapy treatment because of any malignancy expected to last ≥2 months at time of recruitment for myelosuppressive therapy, or at least 1 cycle of myeloablative chemotherapy followed by hematopoietic stem cell transplantation

• Age ≥1 month and \<18 years at time of recruitment

• Written informed consent from patients and/or parents

Locations
Other Locations
Switzerland
Childrens' Clinc Bern, Inselspital Bern
RECRUITING
Bern
Contact Information
Primary
Eva K Brack, MD, PhD
eva.brack@insel.ch
+41316641943
Backup
Roland Ammann, MD, Prof.
info@statconsultammann.ch
Time Frame
Start Date: 2025-02-01
Estimated Completion Date: 2028-06-30
Participants
Target number of participants: 250
Treatments
Experimental: Intervention With CFM alerts arm
* Routine clinical care, which includes, among others, discrete fever measurements using ear thermometers in case of clinical deterioration or suspected fever, at the discretion of patients where applicable, parents and the treating team~* Plus CFM with a CORE® WD running, with alerts being sent automatically to participants if the CFM detects an estimated core body temperature fulfilling the fever criterion of the respective study site (≥38.5°C or 39.0°C).
No_intervention: Control Without CFM alerts arm
* Routine clinical care as in With CFM alerts~* Plus CFM with a CORE® WD running as in With CFM alerts, but with alerts being sent only if a clinically dangerous temperature of ≥40.0°C is detected, which will very rarely be the case before fever is detected by routine clinical care.
Related Therapeutic Areas
Sponsors
Collaborators: ETH Zurich
Leads: Insel Gruppe AG, University Hospital Bern

This content was sourced from clinicaltrials.gov